Imagine Google Maps but for medicines — you type in what you need and instantly see every option available, prices, and the nearest pharmacy that stocks it. Pharmawizard pulls official government drug databases and turns them into a simple mobile app anyone can use. It helps people find cheaper alternatives to their prescriptions and manage what they take, while giving pharmacies and drug companies real insight into what patients actually want. Think of it as a price-comparison site like Skyscanner, but for pills instead of flights.
Consumers struggle to compare medication options, find affordable alternatives, and locate nearby pharmacies — all while navigating confusing official drug databases that were never designed for public use. At the same time, pharmacies and pharmaceutical companies lack direct digital channels to reach informed, active medication buyers.
A mobile medication comparison and management app (Pharmawizard) that pulls official drug data from national and European medicine agencies. The project delivered a full Italian market release, A/B tested beta versions, and a European expansion version targeting Spain and Germany or UK markets.
If you are a pharmacy chain struggling with customer retention and competition from online drugstores — this project built a mobile platform that connects pharmacies directly with consumers searching for medications. The app uses official public drug data to let users compare products and find nearby pharmacies, driving foot traffic to physical stores across Italy, Spain, and Germany or the UK.
If you are a pharmaceutical company looking for better ways to promote products directly to informed consumers — this project developed a data-driven mobile channel that sits between official drug registries and end users. Companies in the healthcare market can use the platform to understand patient behavior and promote products to users actively searching for medication information.
If you are a digital health company looking to expand into medication management — this project created a working mobile solution that normalizes official drug data from national and European medicine agencies into a consumer-friendly interface. The platform was built for multi-country deployment across Italy, Spain, and Germany or UK markets, with a proven freemium business model.
The core medication data is provided for free to consumers, following an open-data philosophy. Revenue comes from value-added services built on top of the data, targeting both citizens and healthcare companies. Specific pricing for B2B services is not disclosed in the project data.
Yes. The project was designed for multi-country deployment. It launched first in Italy with a full market release, then expanded to Spain and one of Germany or UK. The architecture normalizes data from national and European medicine agencies, making it adaptable to additional EU markets.
The platform was developed entirely by DATAWIZARD SRL, the sole consortium partner and an Italian SME. This means IP ownership is concentrated with one company, which could simplify licensing negotiations. Contact the coordinator for licensing terms.
The platform works with official public data from Ministries and National and European medicine agencies. It provides government-verified drug information rather than generating its own medical claims, which positions it as an information service rather than a medical device.
The project delivered a full market release for Italy and a candidate release for the European version targeting Spain and Germany or UK. The technology reached deployment stage by the project end in May 2018, suggesting it is ready for integration or partnership discussions.
Based on available project data, the platform supports interactions between citizens and healthcare businesses including pharmacies, physicians, hospitals, and public health services. Specific API or integration details are not described in the available deliverables.
This is a single-company project: DATAWIZARD SRL, an Italian SME that received SME Instrument Phase 2 funding. With 100% industry composition and no university or research partners, this is purely a commercial venture backed by EU innovation funding. The absence of academic partners means the technology is business-driven rather than research-driven, which is a positive signal for commercial readiness. However, having just 1 partner in 1 country means the European expansion (Spain, Germany/UK) relied entirely on the company's own capacity to enter new markets.
DATAWIZARD SRL is an Italian SME. Use Google AI Search to find the coordinator's direct contact for licensing or partnership inquiries.
Want to explore licensing this medication comparison platform for your market? SciTransfer can connect you directly with the DATAWIZARD team and help structure a partnership deal.
